PTEN and breast carcinoma: Based on emerging data that loss of PTEN may represent a potential mechanism for resistance to checkpoint inhibitors, combinations of a triplet regimen of AKT inhibitor, programmed death-ligand 1 (PD-L1) inhibitor and chemotherapy are also being explored in the setting of advanced breast cancer (28).